Development
Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2023 | 08/31/2023 | 05/31/2023 | 02/28/2023 | 11/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 56.99% | 31.52% | -15.15% | -61.55% | -72.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.99% | 31.52% | -15.15% | -61.55% | -72.26% |
| Cost of Revenue | 37.63% | 23.07% | 5.56% | -19.58% | 34.18% |
| Gross Profit | 86.97% | 40.24% | -28.53% | -74.07% | -87.57% |
| SG&A Expenses | -45.99% | -52.11% | -44.50% | -32.05% | 60.92% |
| Depreciation & Amortization | 5.95% | -6.85% | -14.86% | -22.15% | 2.35% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.52% | -42.14% | -40.25% | -32.56% | 45.44% |
| Operating Income | 44.48% | 52.99% | 45.03% | 20.59% | -199.11% |
| Income Before Tax | 64.11% | 68.81% | 66.00% | 57.12% | -362.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 64.11% | 68.81% | 66.00% | 57.12% | -362.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.11% | 68.81% | 66.00% | 57.12% | -362.87% |
| EBIT | 44.48% | 52.99% | 45.03% | 20.59% | -199.11% |
| EBITDA | 48.65% | 56.11% | 47.12% | 18.94% | -281.05% |
| EPS Basic | 63.62% | 68.46% | 65.97% | 57.16% | -293.82% |
| Normalized Basic EPS | 35.89% | 45.80% | 41.09% | 18.22% | -136.19% |
| EPS Diluted | 63.62% | 68.46% | 65.97% | 57.16% | -293.82% |
| Normalized Diluted EPS | 35.89% | 45.80% | 41.09% | 18.22% | -136.19% |
| Average Basic Shares Outstanding | -0.42% | 0.71% | 4.32% | 10.00% | 19.10% |
| Average Diluted Shares Outstanding | -0.42% | 0.71% | 4.32% | 10.00% | 19.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |